Breaking News

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

Vallon Prescription drugs Inc.

Philadelphia, PA, April 22, 2022 (Globe NEWSWIRE) — Vallon Prescribed drugs, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical enterprise primarily targeted on the advancement of novel medication that are made to prevent abuse in the remedy of CNS issues, right now declared it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to assess strategic options for the Enterprise with the target of maximizing shareholder worth.

Ladenburg has been engaged to suggest Vallon on the strategic evaluate process, which could include, without limitation, exploring the potential for a probable merger, business mix, expenditure into the Enterprise, or a obtain, license or other acquisition of belongings. This procedure may well not consequence in any transaction and the Firm does not intend to disclose extra aspects until and right until it has entered into a precise transaction. Thompson Hine LLP serves as Vallon’s legal counsel and will aid with the exploration of possibilities.

The Business is continuing to assess the very best path forward for ADAIR, its novel abuse-deterrent formulation of amphetamine for the cure of notice deficit hyperactivity ailment (ADHD) and narcolepsy, and for ADMIR, its novel abuse-deterrent formulation of methylphenidate (Ritalin). In the meantime, and in conjunction with the exploration of strategic alternatives, the Enterprise is streamlining its operations in buy to protect its capital and cash assets.

About Vallon Pharmaceuticals, Inc.

Vallon Pharmaceuticals, Inc. is a scientific-stage biopharmaceutical enterprise, headquartered in Philadelphia, PA. The Corporation is focused on the progress of new drugs to aid sufferers with CNS disorders. The Company’s lead investigational solution prospect, ADAIR, is a novel abuse-deterrent formulation of amphetamine speedy launch becoming made for the therapy of ADHD and narcolepsy.

For extra facts about the company, make sure you go to www.vallon-pharma.com or connect with us on LinkedIn or Twitter.

References and backlinks to web sites have been provided for benefit, and the facts contained on any these web page is not a component of, or incorporated by reference into, this push release. Vallon is not liable for the contents of 3rd-celebration sites.

Forward Wanting Statements

This push launch includes “forward-seeking statements” that are based on Vallon’s present-day anticipations and issue to inherent uncertainties, challenges and assumptions that are tricky to forecast, together with, without limitation, Vallon’s means to execute its small business prepare, proceed its growth and fund its ongoing small business routines as prepared, Vallon’s expectations with respect to its strategic assessment method and any likely strategic transactions, Vallon’s ability to develop and commercialize its product or service candidates, Vallon’s anticipations related to results of scientific trials and reports, Vallon’s expectations with respect to the assessment of data and success from its pivotal SEAL study evaluating ADAIR, Vallon’s anticipations with regard to the continued development of ADAIR and ADMIR, Vallon’s anticipations with respect to the significant strengths it believes its abuse-deterrent formulation of medication have in excess of comparable medicine in the market and the rising want for abuse-deterrent formulations of medications, Vallon’s means to make the most of the 505(b)(2) regulatory pathway, Vallon’s capacity to attain Fda approval of ADAIR and its other products candidates, Vallon’s anticipations with respect to its income runway and its means to attain value reduction goals. Ahead-seeking statements may possibly be identified by the use of phrases these as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the detrimental of these words and phrases or other identical expressions. Additional, specific ahead-wanting statements are based on assumptions as to upcoming gatherings that may perhaps not verify to be accurate. These and other threats and uncertainties are described more thoroughly in the portion titled “Risk Factors” in Vallon’s Quarterly and Once-a-year Reviews submitted with the U.S. Securities and Trade Commission. Ahead-wanting statements contained in this announcement are built as of this day, and the Enterprise undertakes no duty to update this sort of details except as required below relevant legislation.

Trader Get hold of:
JTC Workforce, LLC
Jenene Thomas
(833) 475-8247
[email protected]